

# Huihui Yue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5611246/publications.pdf>

Version: 2024-02-01

10  
papers

908  
citations

1163117

8  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

2197  
citing authors

#	ARTICLE	IF	CITATIONS
1	A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019. Chinese Medical Journal, 2022, 135, 368-370.	2.3	16
2	Repurposed Tocilizumab in Patients with Severe COVID-19. Journal of Immunology, 2021, 206, 599-606.	0.8	17
3	MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program. Science Advances, 2021, 7, .	10.3	101
4	Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis. Chest, 2020, 157, 1175-1187.	0.8	137
5	Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19. Annals of Internal Medicine, 2020, 172, 629-632.	3.9	396
6	Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19. Annals of Internal Medicine, 2020, 173, 324.	3.9	42
7	Clinical characteristics of COVID-19 patients with asthma in Wuhan, China: a retrospective cohort study. Journal of Asthma, 2020, , 1-9.	1.7	10
8	The epidemiology and clinical characteristics of coâ€infection of SARSâ€CoVâ€2 and influenza viruses in patients during COVIDâ€19 outbreak. Journal of Medical Virology, 2020, 92, 2870-2873.	5.0	131
9	Outpatient strategies and the changing SARS-CoV-2 epidemic. ERJ Open Research, 2020, 6, 00111-2020.	2.6	2
10	Blockade of JAK2 protects mice against hypoxiaâ€induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation. Cell Proliferation, 2020, 53, e12742.	5.3	56